FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics
Lantheus receives FDA approval for PET imaging agent used to evaluate adults for Alzheimer's disease by identifying tau pathology.
Lantheus got permission from the government to sell a special scanner medicine that helps doctors see Alzheimer's damage in people's brains. This is good news because it means the company can now make and sell this new product, which could help the business grow.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.